Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation
ACCESSWIRE•13/10/2026•08:30 ET
0
Key Highlights
- ➤Tempus Next Pathways lifted guideline-directed biomarker testing from 73% to 84%
- ➤BMS and Microsoft launched a multi-year AI imaging collaboration in its first phase
- ➤FDA-cleared AI algorithms will flag hard-to-detect lung cancer nodules
- ➤Microsoft collaboration is recruiting rural hospitals and community clinics as pilot sites
- ➤More than half of patients with detected lung nodules lack proper follow-up care
NORTHAMPTON, MA / ACCESS Newswire / October 13, 2026 / Can AI help close care gaps in lung cancer?
Lung cancer remains the leading cause of cancer death in the United States, with the American Cancer Society projecting about 229,000 new diagnoses and 125,000 deaths in 2026 alone. Behind those numbers lies another part of the story: Medically underserved communities, including many rural areas, experience higher mortality rates for lung cancer and are also less likely to undergo routine screening or biomarker testing.
Get started
Create a free account to read the full story.